Recent Updates
Recently added Catalysts
RIGL Positive Sentiment Score: 65/100

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Friday, April 4, 2025 1 min read
Key Takeaway: Rigel Pharmaceuticals, Inc. has announced the granting of stock options and restricted stock units pursuant to its Inducement Plan. This is in accordance with NASDAQ Listing Rule 5635(c)(4) and is aimed at incentivizing new employees to join the company. Specifically, 23,350 awards were granted to seven non-executive employees, which will vest over a four-year period with a one-year cliff. Rigel is committed to advancing therapies for hematologic disorders and cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel is expanding its workforce with inducement grants.
  • The stock options and restricted stock units may attract new talent.
  • The strategic move aligns with the company's growth and development goals.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 23,350 stock options and restricted stock units to seven non-executive employees vesting over four years with a one-year cliff.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
SOURCE Rigel Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What did Rigel Pharmaceuticals announce on April 4, 2025?

Rigel Pharmaceuticals announced the granting of stock options and restricted stock units to employees.

How many employees received awards from Rigel Pharmaceuticals?

Seven non-executive employees were granted awards by Rigel Pharmaceuticals.

What is the vesting period for the awarded stock options?

The granted stock options vest over four years with a one-year cliff.

What is Rigel Pharmaceuticals focused on?

Rigel Pharmaceuticals is dedicated to developing therapies for hematologic disorders and cancer.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals NASDAQ employee incentives stock options biotechnology
Last updated: Apr 4, 2025